Patient tailored anti-tumour T cells to prevent relapse in patients with acute myeloid leukaemia undergoing allogeneic haemopoietic stem cell transplantation

为患者量身定制抗肿瘤T细胞，以预防接受同种异体造血干细胞移植的急性髓系白血病患者复发

• 批准号: nhmrc : 1089398
• 负责人: Dr Emily Blyth
• 金额: $ 12.7万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/patient-tailored-anti-cell-transplantation/519252
• 关键词: Patient; tailored; anti; tumour; cells

Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults. Patients with high-risk AML have a 2-year survival of less than 20%. Blood or bone marrow transplant from a healthy donor is often the only chance of cure but the leukaemia frequently returns. Dr Blyth will perform a clinical trial giving leukaemia fighting immune cells from the transplant donor to patients with high risk AML to prevent relapse after transplant.

急性髓性白血病（AML）是成人中最常见的急性白血病。高风险AML患者的2年生存率低于20%。从健康捐献者身上进行血液或骨髓移植通常是治愈的唯一机会，但白血病经常复发。Blyth博士将进行一项临床试验，将移植供体的抗白血病免疫细胞给予高危AML患者，以防止移植后复发。